US 12,324,819 B2
Composition containing Enterococcus faecalis as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby
Jin Ho Lee, Seoul (KR); and Sun Hong Kim, Wonju-si (KR)
Assigned to DOCTOR TJ CO., LTD, Wonju-si (KR)
Appl. No. 17/616,088
Filed by DOCTOR TJ CO., LTD, Wonju-si (KR)
PCT Filed Oct. 21, 2020, PCT No. PCT/KR2020/014364
§ 371(c)(1), (2) Date Dec. 2, 2021,
PCT Pub. No. WO2021/080298, PCT Pub. Date Apr. 29, 2021.
Claims priority of application No. 10-2019-0133242 (KR), filed on Oct. 24, 2019.
Prior Publication US 2022/0313750 A1, Oct. 6, 2022
Int. Cl. A61K 35/744 (2015.01); A23L 33/135 (2016.01); A61P 3/04 (2006.01)
CPC A61K 35/744 (2013.01) [A23L 33/135 (2016.08); A61P 3/04 (2018.01)] 6 Claims
OG exemplary drawing
 
1. A method for inhibiting adipogenesis in adipocytes, the method comprising administering to a subject a pharmaceutically effective amount of killed bacteria of Enterococcus faecalis EF-2001.